Ask AI
ProCE Banner Series

Advancing First-Line Treatment for Patients with HER2 (ERBB2)-Mutant mNSCLC

This program presents the HERm+ mNSCLC disease state and a recently approved IL and 2L treatment option.

Key Takeaways

  • Understand the importance of NGS testing for HERm+ mNSCLC
  • Understand the publicly available data and NCCN Guidelines that inform HER2m+ mNSCLC treatment decisions
  • Understand the full prescribing information for HERNEXEOS (zongertinib tablets)

All Events

Advancing First-Line Treatment for Patients with HER2 (ERBB2)-Mutant mNSCLC

Upcoming Events

October

14

2026

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Boehringer Ingelheim

Boehringer Ingelheim